Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods

Overview

The Therapeutic Goods Act 1989 was enacted to establish a national scheme for regulating therapeutic goods in Australia, ensuring that these goods meet safety, quality, and efficacy standards. The Act addresses the need for a cohesive and comprehensive regulatory framework to protect public health by controlling the supply, advertising, and importation of therapeutic goods. The Therapeutic Goods Administration, under the Department of Health, is responsible for the administration of this Act, with a policy objective to safeguard the health of Australians through the regulation of therapeutic goods. This legislation was introduced to fill the gap in national coordination and oversight of therapeutic goods, which was previously managed by individual states and territories. The revocation of manufacturing licenses, as demonstrated in the recent Gazette publication, underscores the regulatory body's commitment to maintaining high standards and ensuring compliance within the industry. The revocations noted for Quality Herbal Extracts Pty Ltd, Peter MacCallum Cancer Institute, and Sandoz Pty Ltd were made at the request of the manufacturers themselves, highlighting a cooperative approach in upholding the regulatory standards set by the Therapeutic Goods Act 1989.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration (TGA) under the Department of Health, provides the legal framework for regulating therapeutic goods in Australia, encompassing medicines, medical devices, and other health-related products. This Act applies to both individuals and entities involved in the manufacture, supply, and advertising of therapeutic goods within Australia. The scope of the Act extends across the Commonwealth, ensuring a uniform regulatory approach nationwide. The Act mandates licensing for entities that manufacture therapeutic goods, ensuring compliance with stringent quality and safety standards. However, certain products may be subject to exclusions or exemptions as outlined in subordinate instruments, which can provide specific conditions or categories of products that are not subject to the full regulatory requirements of the Act. The revocation of a manufacturing licence, as evidenced by the recent notice, underscores the TGA's commitment to maintaining high standards of safety and efficacy in the therapeutic goods market, with revocations being issued at the request of the manufacturer or as a regulatory measure.

Key Provisions

The Therapeutic Goods Act 1989 provides for the regulation of therapeutic goods in Australia, including the issuance and revocation of manufacturing licenses. Section 41(1)(d) of the Act allows the Secretary to revoke a licence to manufacture therapeutic goods in specific circumstances. This notice, issued under the authority of the Delegate of the Secretary, informs the public of the revocation of three manufacturing licences (Section 41(1)(d)). The revocations pertain to Quality Herbal Extracts Pty Ltd, Peter MacCallum Cancer Institute, and Sandoz Pty Ltd. Each of these entities had their licences revoked at their own request. Entities holding a licence to manufacture therapeutic goods under the Therapeutic Goods Act 1989 have specific obligations, including adherence to good manufacturing practices, maintaining records, and reporting any adverse events related to the goods they produce. These obligations ensure that the therapeutic goods manufactured are safe, of high quality, and meet the standards set out in the Act. The revocation of a licence signifies that the entity is no longer authorised to manufacture therapeutic goods, and they must cease any manufacturing activities immediately. The revocation notice also serves as an official record of the entity's compliance with the Act by voluntarily relinquishing their licence. Breaches of the Therapeutic Goods Act 1989 can lead to both civil and criminal consequences. For instance, manufacturing therapeutic goods without a valid licence is an offence that can result in substantial penalties. Under the Act, individuals or entities found guilty of manufacturing therapeutic goods without a licence can face fines of up to $1,260,000 for a corporation, and imprisonment for up to five years for an individual. These severe penalties underscore the importance of complying with the regulatory requirements set out in the Act to ensure the safety and quality of therapeutic goods available in Australia.